LifeMD, Inc.® (Nasdaq: LFMD), a leading provider of virtual
primary care services, and Withings Health Solutions, a leader in
digital health technology, announce a new strategic partnership
designed to revolutionize weight management patient care by
providing LifeMD’s GLP-1 weight-loss patients with Withings
advanced in-home health monitoring devices, including the Body Pro
2 scale and the BPM Connect Pro blood pressure monitor. With these
devices, LifeMD is setting a new standard in virtual care by
providing clinicians with near real-time and actionable patient
data that can drive compliance, enhance clinical decision-making,
encourage preventive healthcare and, most importantly, improve
long-term outcomes.
LifeMD’s GLP-1 weight-loss program is uniquely
positioned to support patients on their weight-loss journey and
make healthy living accessible by providing online consultations
with licensed clinicians, prescriptions for weight management
medications and orders for full-service laboratory testing. By
leveraging the detailed health data from Withings’ in-home health
monitoring devices, LifeMD aims to gain deeper insight into the
effectiveness of GLP-1 treatments and their impact on overall
health. This partnership also lays the groundwork for pioneering
real-world evidence studies.
“Our partnership with Withings supports a key
corporate objective of building a significant chronic care
management business,” said Anthony Puopolo, M.D., President, LifeMD
Affiliated P.C.s. “Many patients currently treated by our
affiliated medical group for weight management have heart disease,
diabetes or other chronic conditions. Accessible interaction with a
virtual provider — combined with diagnostics, remote patient
monitoring and in-home tools like those offered by Withings — can
improve patient outcomes and reduce the cost of care for chronic
diseases.”
“By being one of the first to monitor body
composition in GLP-1 weight-loss programs, LifeMD is pioneering a
comprehensive approach to weight management. This collaboration
underscores our shared commitment not just to weight management,
but to a deeper understanding of a patient’s health,” said Antoine
Robiliard, VP Withings Health Solutions. “LifeMD's dedication to
leveraging advanced technology to enhance the patient experience
aligns perfectly with our vision. Our cellular devices, with
patient engagement features, will help LifeMD’s teams drive
consistent patient engagement and benefit from larger datasets to
make more informed decisions.”
Body Pro 2 is the first cellular body composition
scale that measures weight and provides a comprehensive analysis of
body composition including body fat, muscle mass, water percentage
and bone mass. With Body Pro 2, LifeMD benefits from a device that
puts patient care at the forefront with features such as
Personalized Health Nudges, allowing care teams to send
personalized messages to patients through the scale’s screen, and
ProgramMemberID, Withings exclusive patient recognition feature to
assure the measurement came from the patient rather than from
another user.
BPM Connect Pro offers medically accurate blood
pressure monitoring, enabling healthcare providers to track changes
in blood pressure alongside weight-loss progress. As GLP-1
medications can lower the risk of cardiovascular events, BPM
Connect Pro offers LifeMD-affiliated providers a comprehensive view
of their patients’ progress and the knowledge to adjust their
medications, if necessary.
Both devices utilize cellular connectivity,
ensuring that LifeMD receives HIPAA-compliant, accurate and
reliable measurements continuously, displayed in near real-time via
the LifeMD patient portal for use by the patient and clinical team.
Thanks to cellular connectivity, the devices work right out of the
box and require no installation.
This partnership not only is a significant
advancement in GLP-1 weight-loss treatment, but it also exemplifies
the potential of digital health technology to transform patient
care and outcomes in the virtual care landscape.
About LifeMD, Inc.LifeMD is a
leading provider of virtual primary care. LifeMD offers
telemedicine, laboratory and pharmacy services, and specialized
treatment across more than 200 conditions, including primary care,
men’s and women's health, weight management, and hormone therapy.
The Company leverages a vertically-integrated, proprietary digital
care platform, a 50-state affiliated medical group, and a US-based
patient care center to increase access to high-quality and
affordable care. For more information, please visit LifeMD.com.
About Withings and Withings Health
Solutions Withings created the first smart scale in
2009 and has been the pioneer in connected health ever since. Its
clinically validated and multi-award-winning products are used by
millions worldwide and include smart scales, hybrid watches, blood
pressure monitors, sleep analyzers and more.
Withings Health Solutions is a dedicated division
of global connected health leader Withings, serving healthcare
professionals across chronic disease prevention and management,
remote patient monitoring, clinical research and more. Its mission
is to bridge the gap between patients and their care teams by
continuously and effortlessly providing healthcare professionals
with medical-grade data generated by patients from an ecosystem of
connected devices. For more than a decade, Withings has built an
expertise in user experience, engagement and retention. Withings
Health Solutions extends this expertise to the healthcare industry
to remove friction in the patient's journey and allow for digital
health to expand. For more information, visit
www.withingshealthsolutions.com.
LifeMD Cautionary Note Regarding
Forward-Looking StatementsThis news release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended; Section 21E of the Securities
Exchange Act of 1934, as amended; and the safe harbor provision of
the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements contained in this news release may be
identified by the use of words such as: “believe,” “expect,”
“anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,”
“estimate,” “predict,” “continue,” and “potential,” or, in each
case, their negative or other variations or comparable terminology
referencing future periods. Examples of forward-looking statements
include, but are not limited to, statements regarding our financial
outlook and guidance, short and long-term business performance and
operations, future revenues and earnings, regulatory developments,
legal events or outcomes, ability to comply with complex and
evolving regulations, market conditions and trends, new or expanded
products and offerings, growth strategies, underlying assumptions,
and the effects of any of the foregoing on our future results of
operations or financial condition.
Forward-looking statements are not historical facts
and are not assurances of future performance. Rather, these
statements are based on our current expectations, beliefs, and
assumptions regarding future plans and strategies, projections,
anticipated and unanticipated events and trends, the economy, and
other future conditions, including the impact of any of the
aforementioned on our future business. As forward-looking
statements relate to the future, they are subject to inherent risk,
uncertainties, and changes in circumstances and assumptions that
are difficult to predict, including some of which are out of our
control. Consequently, our actual results, performance, and
financial condition may differ materially from those indicated in
the forward-looking statements. These risks and uncertainties
include, but are not limited to, “Risk Factors” identified in our
filings with the Securities and Exchange Commission, including, but
not limited to, our most recently filed Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and any amendments thereto. Even if
our actual results, performance, or financial condition are
consistent with forward-looking statements contained in such
filings, they may not be indicative of our actual results,
performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news
release is based on information currently available to us as of the
date on which this release is made. We undertake no obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or otherwise, except as may be
required under applicable law or regulation.
LifeMD
Contacts:InvestorsMarc Benathen, Chief
Financial Officermarc@lifemd.com
MediaJessica Friedeman, Chief
Marketing Officerpress@lifemd.com
Withings Health Solutions Media
Contact:Sarah Smith / Tandem Marketing
Communicationssarah@tandemcomms.com
LifeMD (NASDAQ:LFMDP)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
LifeMD (NASDAQ:LFMDP)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024